Kremers Urban Pharmaceuticals Inc

September 2011
Chain Drug Review;9/26/2011, Vol. 33 Issue 16, p78
Trade Publication
The article profiles Kremers Urban Pharmaceuticals Inc., a subsidiary of Belgium-base UCB SA, which focuses on delivering product solutions and customer service with a commitment to improve products that are needed to get generic products to the U.S. market.


Related Articles

  • Kremers Urban Pharmaceuticals.  // Chain Drug Review;9/28/2015, Vol. 37 Issue 15, p144 

    The article profiles pharmaceutical company Kremers Urban Pharmaceuticals Inc. which is based in Princeton, New Jersey that delivers the product solutions and dedicated customer service needed to get specialty generic products to market without all the perplexity.

  • Kremers Urban Pharmaceuticals.  // Chain Drug Review;9/24/2012, Vol. 34 Issue 16, p127 

    The article profiles the generic pharmaceuticals company, Kremers Urban Pharmaceuticals Inc., located in Princeton, New Jersey.

  • Kremers Urban Pharmaceuticals.  // Chain Drug Review;9/29/2014, Vol. 36 Issue 15, p89 

    The article profiles Kremers Urban Pharmaceuticals in Princeton, New Jersey which delivers product solutions and is committed customer service needed to get specialty generic products into the market.

  • Lannett acquires Kremers Urban.  // Chain Drug Review;9/14/2015, Vol. 37 Issue 14, p11 

    The article reports on the acquisition of the drug firm Kremers Urban Pharmaceuticals Inc. (KU) by the generic drug manufacturer Lannett for 1.23 billion U.S. dollars and mentions that KU's 11 drug applications are pending for approval in the U.S. Food and Drug Administration.

  • Princeton drugmaker fetches $1.23B in sale. Strauss, Eric // njbiz;9/7/2015, Vol. 28 Issue 36, p3 

    The article reports that Lannett Company Inc., a generic drugmaker based in Philadelphia, Pennsylvania, announced in late August 2015 that is has agreed to acquire specialty generics pharmaceutical firm Kremers Urban Pharmaceuticals Inc., a U.S. subsidiary of UCB SA, for 1.23 billion U.S. dollars.

  • Akorn said eyeing tax inversion. Investor's Business Daily // Investors Business Daily;9/15/2014, pA02 

    The specialty-drug maker is exploring a $2 bil bid for Belgian drugmaker UCB's U.S. subsidiary in that country, a deal that would let it move its headquarters overseas to save on taxes, Reuters said, citing sources. UCB was earlier reported to be shopping its U.S. specialty generics unit,...

  • KREMERS URBAN: Solving Your Toughest Problems.  // Drug Topics;Aug2012, Vol. 156 Issue 8, p32s 

    The article profiles generic pharmaceutical company Kremers Urban Pharmaceuticals Inc. Kremers provides a wide range of generic drugs, particularly those products that are difficult to produce. Details on the goal and objectives of the company as well as its products and accomplishments in the...

  • BUZZ 'N BYTES.  // Drug Store News;3/17/2014, Vol. 36 Issue 3, p54 

    The article offers brief information several drugs including the moxifloxacin hydrochloride tablets from Teva Pharmaceuticals Industries Ltd., the raberprazole sodium delayed-release tablets from Kremers Urban Pharmaceuticals Inc. and the Sumatriptan Injection from Dr. Reddy's Labs Ltd.

  • ABOUT UCB.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p6 

    The article provides information on UCB, a biopharmaceutical firm based in Brussels, Belgium, with over 8,000 employees in 40 countries, and is listed on the Euronext Brussels under the UCB symbol.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics